Pilcher CD

Estimated dates of detectable infection (EDDIs) as an improvement upon Fiebig staging for HIV infection dating
Facente SN, Grebe PE, Pilcher CD, Busch MP, Murphy G, Welte A

Epidemiology and Infection

(2020)

https://doi.org/10.1017/S0950268820000503
Interpreting HIV diagnostic histories into infection time estimates: analytical framework and online tool
Grebe PE, Facente SN, Bingham JL, Pilcher CD, Powrie A, Gerber J, Priede G, Chibawara T, Busch MP, Murphy G, Kassanjee R, Welte A

BMC Infectious Diseases

(2019)

https://doi.org/10.1186/s12879-019-4543-9
Performance comparison of the Maxim and Sedia Limiting Antigen Avidity assays for HIV incidence surveillance
Sempa JB, Welte A, Busch MP, Hall J, Hampton D, Facente SN, Keating SM, Marson K, Parkin N, Pilcher CD, Murphy G, Grebe PE

PLoS One

(2019)

https://doi.org/10.1371/journal.pone.0220345
Computational analysis of antibody dynamics identifies recent HIV-1 infection
Seaton KE, Vandergrift NA, Deal AW, Rountree W, Bainbridge J, Grebe PE, Anderson DA, Sawant S, Shen X, Yates NL, Denny TN, Liao H, Haynes BF, Robb ML, Parkin N, Santos BR, Garrett NJ, Price MA, Naniche D, Duerr AC, Keating SM, Hampton D, Facente SN, Marson K, Welte A, Pilcher CD, Cohen MS, Tomaras GD

JCI Insight

(2017)

https://doi.org/10.1172/jci.insight.94355
Infection staging and incidence surveillance applications of high dynamic range diagnostic immuno-assay platforms
Grebe PE, Welte A, Hall J, Keating SM, Facente SN, Marson K, Martin JN, Little S, Price MA, Kallas EG, Busch MP, Pilcher CD, Murphy G

Journal of Acquired Immune Deficiency Syndromes

(2017)

https://doi.org/10.1097/QAI.0000000000001537
HIV antibody level as a marker of HIV persistence and low-level viral replication
Keating SM, Pilcher CD, Jain V, Lebedeva M, Hampton D, Abdel-Mohsen M, Deng X, Murphy G, Welte A, Facente SN, Hecht FM, Deeks SG, Pillai SK, Busch MP

The Journal of Infectious Diseases

(2017)

https://doi.org/10.1093/infdis/jix225
Moving towards a reliable HIV incidence test-current status, resources available, future directions and challenges ahead
Murphy G, Pilcher CD, Keating SM, Kassanjee R, Facente SN, Welte A, Grebe PE, Marson K, Busch MP, Dailey P, Parkin N, Osborn J, Ongarello S, Marsh K, Garcia Calleja JM

Epidemiology and Infection

(2017)

https://doi.org/10.1017/S0950268816002910
Comparison of cross-sectional HIV incidence assay results from dried blood spots and plasma
Schlusser KE, Pilcher CD, Kallas EG, Santos BR, Deeks SG, Facente SN, Keating SM, Busch MP, Murphy G, Welte A, Quinn TC, Eshleman SH, Laeyendecker O

PLoS One

(2017)

https://doi.org/10.1371/journal.pone.0172283
Performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay in Detecting “Recent”HIV Infection and Calculating Population Incidence
Keating SM, Kassanjee R, Lebedeva M, Facente SN, Macarthur JC, Grebe PE, Murphy G, Welte A, Martin JN, Little SJ, Price MA, Kallas EG, Busch MP, Pilcher CD

Journal of Acquired Immune Deficiency Syndromes

(2016)

https://doi.org/10.1097/QAI.0000000000001146
Viral load criteria and threshold optimization to improve HIV incidence assay characteristics
Kassanjee R, Pilcher CD, Busch MP, Murphy G, Facente SN, Keating SM, McKinney E, Marson K, Price MA, Martin JN, Little SJ, Hecht FM, Kallas EG, Welte A

AIDS

(2016)

https://doi.org/110.1097/QAD.0000000000001209
Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository
Kassanjee R, Pilcher CD, Keating SM, Facente SN, McKinney E, Price MA, Martin JN, Little S, Hecht FM, Kallas EG, Welte A, Busch MP, Murphy G

AIDS

(2014)

https://doi.org/10.1097/QAD.0000000000000429